Race Oncology Ltd (ASX:RAC, OTC:RAONF) CEO Daniel Tillett joins Jonathan Jackson in the Proactive studio to provide an update on the company’s movements over the last few months. Just recently, Race received a $4 million R&D tax incentive tto accelerate clinical development of bisantrene, which is undergoing Phase II trials specifically for Acute Myeloid Leukemia. The clinical-stage biopharmaceutical company develops drugs designed to treat cancer, but is unique in that its novel approach treats the cancer, while protecting the heart. Race has had a strong half of the financial year, executing an exclusive licensing agreement with City of Hope and entering an agreement with Ardena Holding NV, to provide additional current Good Manufacturing Practice (cGMP). The company is now focused on hitting several milestones through 2024.